—At 8th International Congress on Autoimmunity, Visit Booth 17A & Attend May 10 Poster Session—

SAN DIEGO, CA – May 1, 2012 — Genalyte, Inc., a life sciences company developing and commercializing innovative next-generation multiplexing technology, today announced that it will launch an Early Access program for its Maverick™ Detection System and multiplexed autoimmune assays at two major immunology meetings in May. Genalyte will host booths and present scientific data on the performance of the Maverick platform at Immunology 2012™, the 99th Meeting of the American Association of Immunologists, and at the 8th International Congress on Autoimmunity.

Genalyte’s Early Access program enables scientists to gain pre-launch access to multiplexed autoantibody assays and the Maverick platform, which uses a patented silicon chip containing arrays of photonic microring sensors that can simultaneously analyze multiple proteins from a single small sample. ―These meetings will allow us to introduce the unique capabilities of the Maverick platform and our Early Access program to prominent immunology researchers, said Genalyte CEO Cary Gunn. ―Feedback from our Early Access customers should be very helpful as we prepare for full commercialization of the Maverick platform in the coming months.
Maverick Detection System assays do not require the washes, incubations, reagents or other processing steps typically needed for sample preparation. They are simple to use and rapid — results are available in only 15 minutes, including just two minutes of hands-on time. The Maverick platform has a large dynamic range and excellent sensitivity, with good reproducibility and no cross talk.

At Immunology 2012™, Dr. Gunn will host a workshop discussing Genalyte’s Maverick Detection System on May 7, 2012 from 10:00-11:00am in Room 203. Information on the Maverick Detection System will be available at Genalyte’s Booth 103.

At the 8th International Congress on Autoimmunity, Genalyte will present at Poster Session 1 on May 10, 2012 from 10:00am–5:00pm, Poster 1731. Information on the Maverick Detection System will be available at Genalyte’s Booth 17A.

Immunology 2012 will be held in Boston, MA, May 4-8, 2012. For more information, visit http://immunology2012.org.

The 8th International Congress on Autoimmunity will be held in Granada, Spain, May 9-13, 2012. For more information, visit http://www2.kenes.com/autoimmunity/pages/home.aspx.

Download PDF of this press release here

About Genalyte

Founded in 2007, Genalyte, Inc. is commercializing the Maverick™ detection platform based on the company’s revolutionary Microring Sensor Technology™, a new approach to multiplexing that leverages advances in silicon photonics to reduce or eliminate sample preparation, provide scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieve excellent sensitivity and up to eight logs of dynamic range.

Contacts:
Genalyte, Inc.
Martin Gleeson
VP, Development & Applications
+1 858 750-4470
martin@genalyte.com

Media:
BLL Partners, LLC
Barbara Lindheim
+1 212 584-2276
blindheim@bllbiopartners.com

Responsibilities:

• Assist in the development of multiplexed, microarray-based products for autoimmune antibodies and biomarkers; direct experience with anti-nuclear antibody assays and/or multiplexed sandwich immunoassays is highly desirable
• Conduct experiments to optimize chip surface properties, microarraying procedures, and product performance and stability
• Work closely with Engineering and Software personnel during instrument and user interface development
• Careful record keeping of materials, methods and data, and documentation of results
• Preparation of SOPs, reports and summaries
• Maintenance of laboratory equipment
• Preparation of common and critical reagents
• Work with human serum samples
• Assist in data analysis using Excel and graphing programs such as SigmaPlot

Education and Qualification Requirements:

• A BS degree in biological, chemical or physical sciences and 1-4 years of industrial experience in R&D or product development roles
• Good hands-on lab skills with attention to detail
• Ability to multi-task, handle changing job functions, and rapidly learn new techniques
• Team player with the ability to work closely with others having diverse expertises and backgrounds

Please submit your resume for consideration.
Note: Local applicants only

About us
Genalyte, Inc. is a biomedical company developing sensing instrumentation for research and diagnostic use. The company is venture funded and has prospects for tapping into vast biomedical research and diagnostic markets with its novel label-free, multiplexed sensing technology. We welcome you to become part of a vibrant team with avenues of professional growth and success.

Responsibilities:

• Design and develop various applications and graphical user interface(s) for biomedical instrumentation under the guidance of product development procedures tailored for success in biomedical regulatory environments (FDA, CLEA)
• Interact with marketing and regulatory advisement teams to gather requirements and assist in construction of software requirement specifications (SRS) as well as validation and verification (V&V) protocols for the final product
• Develop a web interface between the instrument host PC and factory servers to communicate instrument logs over Ethernet.
• Port existing data processing algorithms (written in Matlab) into a flexible and modular graphical user interface.
• Data encryption and storage of the raw data produced by the instrument with flexible data access protocols
• Participate in efforts to construct a database system and develop an interface between the instrument and the database.
• Participate in code design reviews, construct software documentation and maintain source code under version control and logging.

Qualification and Requirements:

• Bachelor’s Degree (MS preferred) in Computer Science or related field
• At least 6+ years of relevant industry experience with design of user interfaces and windows based applications in regulatory controlled environments. Experience with software development for FDA targeted products is preferred
• Proficiency in object oriented design, software architecture, and programming
• Strong understanding of operating systems, data structures and theory of automata along with cross-platform compatibility and design constraints
• Experience with TCP/IP (socket-level) programming and internetwork protocol messaging at the application level.
• Experience with high-speed serial interface programming in both synchronous and asynchronous regimes
• Preference to applicant with experience utilizing .NET C# and use of MS Charts for display of captured data as well as plotting of statistical functions
• Familiarity with database architecture development MS SQL or other
• Must have excellent oral and written communication and problem solving skills
• Should have a proactive approach and be able to work within a team boasting diverse expertise and backgrounds.

About us:
Genalyte, Inc. is a biomedical company developing multiplexed assays in conjunction with its novel and highly advantageous detection platform for research and diagnostic use.  The company is privately funded and has prospects for tapping into vast biomedical research and diagnostic markets.  We welcome you to become part of a vibrant team with avenues for professional growth and success.  For more information regarding our company and products, please visit us at www.genalyte.com.

Responsibilities:

• Lead the development of multiplexed, microarray-based diagnostic products for autoimmune antibodies and disease biomarkers; direct experience developing ANA assays and/or sandwich immunoassays is required
• Contribute to multiple projects both through hands-on experimentation and by supporting team members
• Develop expertise in chip surface modification and characterization, microarraying a variety of materials, and maximizing product shelf-life
• Communicate with Engineering and Software personnel during instrument and user interface feature expansion, as well as will Marketing representatives to define product design requirements
• Prepare or oversee preparation of SOPs, data summaries, study reports and project summaries for cross-functional team
• Work with human serum samples

Education and Qualification Requirements:

• PhD in biological, chemical or physical sciences and 1-4 years of industrial experience in R&D or product development roles; candidates with bachelor degrees plus 10 years of relevant experience will also be considered
• Knowledge of FDA 510(k) submission and CE certification, and supervisory experience are preferred
• Ability to multi-task, handle changing job functions, and rapidly learn new techniques
• Must be a team player with the ability to work closely with others having diverse expertises and backgrounds

Please submit your resume for consideration.
Note: Local candidates preferred; no relocation benefits

About Us:
Genalyte, Inc. is a biomedical company developing sensing instrumentation for research and diagnostic use. The company is venture funded and has prospects for tapping into vast biomedical research and diagnostic markets with its novel label-free, multiplexed sensing technology. We welcome you to become part of a vibrant team with avenues of professional growth and success.

—Maverick Platform is Much Simpler, Faster and More Sensitive, Flexible and Cost-Effective than Current Options—

 SAN DIEGO, CA – March 30, 2012 — Genalyte, Inc., a life sciences company developing and commercializing innovative next-generation multiplexing technology, today announced completion of an $11.8 million Series B financing.  New investors Redmile Group and Claremont Creek Ventures and private investors from Genalyte’s Series A round participated in the Series B financing.  Genalyte intends to use the new funds primarily for commercialization of its Maverick^TM platform and its highly multiplexed panels for autoimmune and immunoassay applications.

Genalyte has pioneered an entirely new approach to immunodetection using silicon chip manufacturing methods. The Maverick platform uses a technology called silicon photonics to directly measure protein binding between antibodies and antigens or hybridization of nucleic acids.  This technology eliminates the need for complex processing associated with current multiplexed testing, while leveraging the manufacturing advantages of silicon chips.  Genalyte is preparing to launch the Maverick platform this summer, initially addressing the autoimmunity research and testing markets.

“By applying advances in silicon photonics to the life sciences, we have been able to develop a completely new approach to biological detection that provides major advantages to researchers and, eventually, to clinicians,” commented Genalyte CEO and founder Cary Gunn.  “Our initial funding enabled us to fully develop and refine the silicon photonics biosensor consumables that are the heart of the Maverick system, along with the instrument itself and our initial multiplexed immunology panels.  This new financing provides us with the resources to launch the platform in the coming months and to begin to populate it with a wide variety of proprietary assays for multiple applications.”

The Maverick platform runs scalable multiplexed assays using a silicon chip that contains arrays of photonic microring sensors that can simultaneously analyze multiple proteins from a single small sample.   Assays do not require the washes, incubations, reagents or other processing steps typically associated with sample preparation.  The assays are therefore simple to use and rapid—results are available in only 15 minutes, including just two minutes of hands-on time.  The Maverick platform has a large dynamic range and excellent sensitivity, with good reproducibility and no cross talk.

Dr. Gunn continued, “By using silicon-based technologies, we can provide customers with unprecedented system performance while leveraging the highly efficient production characteristic of traditional silicon chip manufacturing.  During our four years of development, we and our academic collaborators generated a large number of peer-reviewed studies that provide important validation for the superiority of our detection data and the breadth of applications that are possible.  We look forward to unveiling the Maverick platform at upcoming scientific meetings and to making this exciting new technology available to researchers worldwide.”

Genalyte will be discussing the Maverick platform at several upcoming scientific meetings, including:

Europt(r)ode XI, Optical Chemical Sensors and Biosensors, Barcelona, Spain, April 1-4, 2012, www.europtrodexi.eu/Industrial-session.html

Immunology 2012^TM, the 99^th Meeting of the American Association of Immunologists, Boston, MA, May 4-8, 2012, http://immunology2012.org

8^th International Congress on Autoimmunity, Granada, Spain, May 9-13, 2012,  www2.kenes.com/autoimmunity/pages/home.aspx

Download PDF of this press release here

About Genalyte

Since 2007, Genalyte’s mission has been to develop instrument systems, hardware, software and consumables making multiplex protein and nucleic acid testing from a single sample the standard in the research, life science and clinical diagnostic markets.  Genalyte’s multiplexing platform incorporates the company’s revolutionary Microring Sensor Technology™, a new approach to multiplexing that reduces or eliminates sample preparation, provides scalable multiplexing for both proteins and nucleic acids from a single small sample, and achieves up to eight logs of dynamic range.  Genalyte is preparing to launch the Maverick^TM platform, which uses this technology to run scalable multiplexed assays that do not require the washes, incubations or other processing steps associated with sample preparation.  The Maverick platform has a large dynamic range and excellent sensitivity.

About Claremont Creek Ventures

Claremont Creek Ventures is a seed and early stage venture capital firm investing in digital healthcare, energy technology, payments/commerce, and online businesses.  Claremont Creek has $300 million in capital under management in two funds.  For more information, visit www.claremontcreek.com

Contacts:
Genalyte, Inc.
Martin Gleeson
VP, Development & Applications
+1 858 750-4470
martin@genalyte.com

Media:
BioCom Partners
Barbara Lindheim
+1 212 584-2276 x201
blindheim@biocompartners.com